Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out.
“There’s so much unmet need when you look into retinal diseases,” Musunuri said.
Get the full story at our sister site, Drug Delivery Business News.
The post How this biotech plans to go up against big pharma with its eye disease products appeared first on MassDevice.
from MassDevice http://ift.tt/2zMrIpK
Cap comentari:
Publica un comentari a l'entrada